A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

However, the new law would not be applicable to people ... What medication is available and what are the side effects?

KinCon biolabs, a spin-off from the University of Innsbruck, is expanding its patented platform technology to support ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Scientists said the findings, published in the journal Nature, represent 'a big step forward' in developing new drug ...

‘This is a clear violation of FEMA’s core values and principles to help people regardless of their political affiliation,’ the agency says. A city tram is torched to a chorus of anti-Jewish slurs as ...